Vaxcyte, Inc. Operating Income Loss

• Vaxcyte, Inc. showed a decrease of -62.2% in Operating Income Loss from 2024 to 2025.
• This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Vaxcyte, Inc.'s Operating Income Loss has declined by 2,499.5%.
• Historical annual values: Fiscal year 2025: -$923.68 million | Fiscal year 2024: -$569.55 million | Fiscal year 2023: -$468.04 million | Fiscal year 2022: -$232.26 million | Fiscal year 2021: -$103.67 million | Fiscal year 2020: -$89.58 million | Fiscal year 2019: -$54.15 million | Fiscal year 2018: -$35.53 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026